At IDWeek 2024, Moderna presented interim results from an ongoing Phase I/II, randomised, observer-blind, placebo-controlled, dose-ranging trial (NCT05992935) for mRNA-1403, a prophylactic vaccine ...

However, the trial, sponsored by Moderna, a pharmaceutical and biotechnology company, will evaluate the efficacy, safety and immunogenicity of an investigational norovirus vaccine, mRNA-1403.

The first, an investigational norovirus mRNA vaccine from Moderna (mRNA-1403), safely elicited strong antibody responses in adults against globally prevalent norovirus genotypes, according to ...

Sponsored by Moderna, the trial evaluates the efficacy and safety of a norovirus vaccine called mRNA-1403. There are currently no licensed norovirus vaccines in use anywhere in the world. The phase 3 ...

The company has initiated a Phase 3 clinical trial for its investigational norovirus vaccine, mRNA-1403, which will enroll approximately 25,000 participants worldwide. Moderna's updated COVID-19 ...

Norovirus vaccine: Moderna's trivalent vaccine candidate for the prevention of norovirus (mRNA-1403) advanced into a pivotal Phase 3 randomized clinical trial evaluating its efficacy, safety and ...

However, the trial, sponsored by Moderna, a pharmaceutical and biotechnology company, will evaluate the efficacy, safety and immunogenicity of an investigational norovirus vaccine, mRNA-1403. READ ...

A Phase III clinical trial is being launched in the UK to investigate Moderna’s norovirus vaccine mRNA-1403. This is the ...

Norovirus vaccine: Moderna's trivalent vaccine candidate for the prevention of norovirus (mRNA-1403) advanced into a pivotal Phase 3 randomized clinical trial evaluating its efficacy, safety and ...